Keros Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 26, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	216	398	642	1,266	1,323	1,403
Market Cap Growth	-62.01%	-38.02%	-49.29%	-4.28%	-5.71%	-14.26%
Enterprise Value	-43.42	124.97	98.93	948.29	1,056	1,173
Last Close Price	10.93	20.36	15.83	39.76	48.02	58.51
PE Ratio	-	8.85	-	-	-	-
PS Ratio	6.68	1.63	180.84	8384.12	-	69.79
PB Ratio	0.77	1.31	1.12	3.81	4.77	5.77
P/TBV Ratio	1.23	2.54	1.04	3.52	4.37	5.61
P/FCF Ratio	-	3.76	-	-	-	-
P/OCF Ratio	-	3.70	-	-	-	-
EV/Sales Ratio	-	0.51	27.87	6280.09	-	58.36
EV/EBITDA Ratio	-	1.81	-	-	-	-
EV/EBIT Ratio	-	1.85	-	-	-	-
EV/FCF Ratio	-	1.18	-	-	-	-
Debt / Equity Ratio	0.05	0.05	0.03	0.04	0.05	0.00
Debt / EBITDA Ratio	-	0.24	-	-	-	-
Debt / FCF Ratio	-	0.16	-	-	-	-
Net Debt / Equity Ratio	-0.93	-0.89	-0.95	-0.95	-0.96	-0.94
Net Debt / EBITDA Ratio	2.44	-3.92	2.58	1.87	2.33	4.09
Net Debt / FCF Ratio	4.55	-2.55	3.32	2.49	3.73	3.62
Asset Turnover	0.10	0.51	0.01	0.00	0	0.08
Quick Ratio	22.11	14.36	20.50	13.59	16.86	20.94
Current Ratio	22.62	15.45	21.45	14.25	17.27	21.23
Return on Equity (ROE)	-28.92%	19.90%	-41.46%	-50.19%	-40.22%	-23.27%
Return on Assets (ROA)	-35.88%	14.92%	-42.70%	-50.22%	-40.85%	-20.73%
Return on Invested Capital (ROIC)	-439.84%	225.61%	-915.33%	-1251.82%	-887.57%	-985.85%
Return on Capital Employed (ROCE)	-35.77%	14.92%	-45.14%	-53.45%	-43.02%	-22.30%
Earnings Yield	-	11.30%	-	-	-	-
FCF Yield	-	26.63%	-	-	-	-
Buyback Yield / Dilution	17.49%	-1.13%	-27.14%	-16.66%	-8.17%	-50.48%
Total Shareholder Return	17.49%	-1.13%	-27.14%	-16.66%	-8.17%	-50.48%

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q